The effect of bovine IFN-alpha on the immune response in guinea pigs vaccinated with DNA vaccine of foot-and-mouth disease virus

Acta Biochim Biophys Sin (Shanghai). 2004 Oct;36(10):701-6. doi: 10.1093/abbs/36.10.701.

Abstract

In this study, we constructed recombinant plasmid pcDNA3.1/P12X3C3D including P1, 2A, 3C, 3D and part of 2B gene of FMDV and pcDNA3.1/IFN containing the gene encoding bovine IFN-alpha. We inoculated the DNA vaccine pcDNA3.1/P12X3C3D with or without pcDNA3.1/IFN to evaluate the efficiency of this DNA vaccine and the immunogenicity of DNA vaccine enhanced by the co-delivery with pcDNA3.1/IFN. After two times of vaccination with DNA vaccine, all of guinea pigs were challenged with 103 ID50 FMDV type O. Anti-FMDV antibody levels were detected by ELISA and T lymphocyte proliferation response was tested by MTT assay. The result shows that guinea pigs inoculated by pcDNA3.1/P12X3C3D alone or with pcDNA3.1/IFN generated specific antibodies and induced an FMDV-specific T lymphocyte proliferation response. FMDV challenge tests showed that one in four guinea pigs immunized by pcDNA3.1/P12X3C3D with pcDNA3.1/IFN was protected from the FMDV serotype O infection. This result indicated that the efficiency of the DNA vaccine was enhanced by co-delivery with pcDNA3.1/IFN. However, the protection rate was considerably lower than that immunized with conventional FMD vaccine.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cattle
  • Foot-and-Mouth Disease / immunology
  • Foot-and-Mouth Disease / prevention & control*
  • Foot-and-Mouth Disease / virology
  • Foot-and-Mouth Disease Virus / genetics*
  • Foot-and-Mouth Disease Virus / immunology*
  • Foot-and-Mouth Disease Virus / pathogenicity
  • Genetic Therapy / methods*
  • Genetic Therapy / veterinary
  • Guinea Pigs
  • Histocompatibility Antigens Class II / immunology
  • Interferon-alpha / administration & dosage*
  • Interferon-alpha / genetics
  • Interferon-alpha / immunology*
  • Treatment Outcome
  • Vaccination / methods
  • Vaccines, DNA / administration & dosage*
  • Vaccines, DNA / immunology*
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / immunology

Substances

  • Histocompatibility Antigens Class II
  • Interferon-alpha
  • Vaccines, DNA
  • Viral Vaccines